Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

This randomized double-blind noninferiority trial compared the 18-month efficacy of rituximab + placebo vs cyclophosphamide + azathioprine for the treatment of ANCA-associated vasculitis. Of the 197 patients enrolled, 64% of the patients in the rituximab group, as compared with 53% of the patients in the cyclophosphamide-azathioprine group, had a complete remission by 6 months. The results were similar at 12 and 18 months. The authors concluded that both regimens were effective as both induction and maintenance therapies for ANCA-associated vasculitis over 18 months of follow-up. : Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Trial Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Source: Nephrology Now - Category: Urology & Nephrology Authors: Tags: Clinical Nephrology General Nephrology Glomerulonephritis Source Type: research